Translational Oncology · 2021 · 25 citations · 23 references
MedicineGeneticsOncologyGastrointestinal OncologyMolecular OncologyNeoplasiaAnal CancerCancer Molecular PathologyHuman Papillomavirus InfectionMalignant NeoplasmsMolecular Tumor ProfilingSquamous Cell CarcinomaCancer Driver Gene IdentificationCancer Driver Mutation AnalysisComplete Response AssessmentDefinitive ChemoradiotherapyDisease Prognostic BiomarkersGastrointestinal MalignancyPd-l1 BlockadePrognostic Biomarkers
Anal squamous cell carcinoma (ASCC) is a rare gastrointestinal malignancy associated with high-risk Human papillomavirus (HPV) infection. Despite improved outcomes in non-metastatic ASCC, definitive chemoradiotherapy constitutes the standard treatment for localized disease. Evidences for predictive and prognostic biomarkers are limited. Here, we performed a viral, immune, and mutational characterization of 79 non-metastatic ASCC patients with complete definitive chemoradiotherapy. HPV-16 was detected in 91% of positive cases in single infections (78%) or in coinfections with multiple genotypes (22%). Fifty-four percent of non-metastatic ASCC cases displayed mutations affecting cancer driver genes such as PIK3CA (21% of cases), TP53 (15%), FBXW7 (9%), and APC (6%). PD-L1 expression was detected in 57% of non-metastatic ASCC. Increased PD-L1 positive cases (67%) were detected in patients with complete response compared with non-complete response to treatment (37%) (p = 0.021). Furthermore, patients with PD-L1 positive tumors were significantly associated with better disease-free survival (DFS) and overall survival (OS) compared with patients with PD-L1 negative tumors (p = 0.006 and p = 0.002, respectively). PD-L1 expression strongly impacts CR rate and survival of non-metastatic ASCC patients after standard definitive chemoradiotherapy. PD-L1 expression could be used to stratify good versus poor responders avoiding the associated morbidity with abdominal perineal resection.
23
Rebecca L. Siegel, Elizabeth Ward, Otis W. Brawley et al. · CA A Cancer Journal for Clinicians · 2011 · 4.1K citations · Full text
R.D. James, Rob Glynne‐Jones, Helen Meadows et al. · The Lancet Oncology · 2013 · 733 citations · Full text
John Northover, Rob Glynne‐Jones, David Sebag‐Montefiore et al. · British Journal of Cancer · 2010 · 428 citations · Full text